

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

6-B&C, Pil Court, 6th Floor,
111, M. Karve Road, Churchgate,
Mumbai - 400 020.

Tel.: (+91-22) 4311 5000
E-mail: kjco@kjco.net
Website: www.kjco.net

INDEPENDENT AUDITOR'S REPORT

To
The Board of Directors of
Kopran Laboratories Limited

1. Report on the Audit of Financial Statements

We have audited the accompanying interim financial statements of **Kopran Laboratories Limited ('Company')**, which comprise the Balance Sheet as at December 31, 2024, the Statement of Profit and Loss for the nine months ended on that date, the Statement of Cash Flows for the nine months then ended and notes to the financial statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as "Interim financial statements").

2. Opinion

In our opinion and to the best of our information and according to the explanations given to us, except for the effects of the matter described in the Basis for Qualified Opinion paragraph, the aforesaid interim financial statements give a true and fair view in conformity with Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act, 2013 (the "Act"), read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the state of affairs of the Company as at December 31, 2024, the profit for the nine months ended on that date and its cash flows for the nine months ended on that date.

3. Basis for Opinion

We conducted our audit of interim financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the '*Auditor's Responsibilities for the Audit of the Interim Ind AS Financial Statements*' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the interim financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the interim financial statements.



4. Responsibilities of management and those charged with governance for the Interim Financial Statements

The Company's Management and Board of Directors is responsible for the preparation and presentation of these interim financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income and cash flows of the Company in accordance with the other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the interim financial statements that given true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the interim financial statements, Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial Reporting process.

5. Auditor's Responsibilities for the Audit of the Interim Financial Statements

Our objectives are to obtain reasonable assurance about whether the interim financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these interim financial statements.



-3-

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the interim financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on effectiveness of the Company's internal financial controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the interim financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the interim financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the interim financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the interim financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



-4-

We also provide those charged with governance with statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For KHANDELWAL JAIN & CO.
Chartered Accountants,
Firm Registration No.: 105049W

Bhupendra Karkhanis



(BHUPENDRA KARKHANIS)
PARTNER

Membership No. 108336

UDIN - 25108336BMJNM05215

Place: Mumbai

Date: March 19, 2025

KOPRAN LABORATORIES LIMITED
BALANCE SHEET AS AT DECEMBER 31, 2024

Rs. In Lakhs

Particulars	Note No.	December 31, 2024	March 31, 2024
EQUITY AND LIABILITIES			
Shareholder's Funds			
Share capital	2	530.32	150.00
Reserves and surplus	3	6,728.96	5,596.87
Non - current liabilities			
Long - term borrowings	4	548.62	546.01
Long - term provisions	5	144.17	136.42
Deferred tax liabilities (net)	12	106.86	95.27
Current liabilities			
Short - term borrowings	6	762.80	611.08
Trade payables	7		
(i) Total outstanding dues to micro enterprises and small enterprises		-	-
(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises		1,957.57	1,625.35
Other current liabilities	8	675.67	562.79
Short-term provisions	9	177.19	124.69
Total		11,632.16	9,448.50
Assets			
Non - current assets			
Property, plant and equipment	10	3,239.59	3,042.27
Non current investments	11	282.91	19.35
Other non-current assets	13	3.97	4.41
Current assets			
Inventories	14	1,475.40	697.72
Trade receivables	15	2,202.37	3,319.47
Cash and bank balances	16	3,767.73	1,745.51
Short - term loans and advances	17	401.82	373.98
Other current assets	18	258.37	245.79
Total		11,632.16	9,448.50

Significant accounting policies and Notes forming part of the financial statements

1 to 26

As per our report of even date

For Khandelwal Jain & Co.

Chartered Accountants

Firm Registration No. - 105049W

Bhupendra

BHUPENDRA KARKHANIS
PARTNER

Membership No.108336



For and on behalf of the Board of Directors

Varun Somani
VARUN SOMANI
MANAGING DIRECTOR
DIN No. 00015384

Namrata Somani
NAMRATA SOMANI
DIRECTOR
DIN No. 07095595

Place : Mumbai

Date : 19/03/2025

KOPRAN LABORATORIES LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED DECEMBER 31, 2024

Rs. In Lakhs

Particulars	Note No.	Period ended	Year ended
		December 31, 2024	March 31, 2024
INCOME			
Revenue from operations	19	6,824.76	10,240.47
Other income	20	160.83	104.94
Total income		6,984.59	10,345.41
EXPENDITURE			
Purchase of stock-in-trade	21	3,851.60	4,568.34
Changes in inventories of finished goods, work-in-progress and Stock-in-trade	22	(777.68)	222.97
Employee benefit expense	23	751.10	1,153.14
Financial costs	24	118.56	149.18
Depreciation and amortization expense	10	256.40	294.43
Other expenses	25	1,273.52	1,470.05
Total expenses		5,473.50	7,858.11
Profit before tax		1,512.09	2,487.30
Tax expense			
Current tax		368.42	628.00
Deferred tax		11.58	30.56
Tax impact of earlier years		-	-
Profit after tax		1,132.09	1,828.74
Earning per equity share: (Face Value of Rs. 10 each) Basic and Diluted	26	42.51	121.92
Significant accounting policies and Notes forming part of the financial statements	1 to 26		

As per our report of even date

For Khandelwal Jain & Co.

Chartered Accountants

Firm Registration No. 105049W

Bhupendra Karkhanis
BHUPENDRA KARKHANIS
 PARTNER

Membership No. 108336

Place : Mumbai

Date : 19/03/2025



For and on behalf of the Board of Directors

Varun Somani
VARUN SOMANI
 MANAGING DIRECTOR

DIN No. 00015384

Namrata Somani

NAMRATA SOMANI
 DIRECTOR

DIN No. 07095595

KOPRAN LABORATORIES LIMITED
CASH FLOW STATEMENT

Rs. In Lakhs

Particulars	Period ended	
	December 31, 2024	March 31, 2024
A. Cash Flows from Operating Activities		
Profit before tax	1,512.08	2,487.28
Adjustments for:		
Depreciation	256.40	294.44
Finance cost	118.57	149.18
Interest income	(23.24)	(89.72)
(Profit)/Loss on sale of fixed assets	(0.11)	0.37
Operating Cash Flows before Working Capital Adjustments	1,863.70	2,841.56
Adjustments for:		
(Increase)/ Decrease in long term provision	7.75	16.49
Increase in Trade payables	332.23	580.03
Increase in other current liabilities	112.87	223.92
Increase in short-term provisions	2.60	54.09
Decrease / (Increase) in Other non-current assets	0.44	399.70
Decrease / (Increase) in Inventories	(777.69)	222.97
Increase in Trade receivables	1,117.10	(1,468.61)
Increase in Short-term loans & advances	(27.84)	(22.87)
(Increase) / Decrease in Other current assets	(12.58)	8.22
Cash Generated from Operations	2,618.59	2,855.49
Direct taxes paid	(318.51)	(573.48)
Net Cash Flows from Operating Activities	2,300.08	2,282.01
B. Cash Flows from Investing Activities		
Interest income	23.24	89.72
Purchase of fixed assets	(456.61)	(778.18)
Proceeds from Sale of fixed assets	3.00	25.00
Purchase of Investment	(263.56)	-
Bank balance other than cash and cash equivalent below	239.00	(332.01)
Net Cash Flows from Investing Activities	(454.92)	(995.48)
C. Cash Flows from Financing Activities		
Finance Cost	(118.57)	(149.18)
Proceeds from Right Issue	380.32	-
Proceeds/(repayment) of short term borrowings (net)	151.72	(74.38)
Proceeds from long term borrowings (net)	2.59	515.68
Repayment of long term borrowings	-	(628.15)
Proceeds/(repayment) of loan from directors	-	(320.00)
Net Cash Flows from Financing Activities	416.06	(656.04)
Net Increase in Cash & Cash Equivalents	2,261.21	630.49
Cash & Cash Equivalents		
As at the beginning of the year	830.96	200.46
As at the end of the year	3,092.17	830.96
Net Increase in Cash & Cash Equivalents	2,261.21	630.49
Significant accounting policies and Notes forming part of the financial statements	1 to 26	

As per our report of even date
For Khandelwal Jain & Co.
Chartered Accountants
Firm Registration No. - 105049W

BHUPENDRA KARKHANIS
PARTNER
Membership No.108336



For and on behalf of the Board of Directors

VARUN SOMANI **NAMRATA SOMANI**
MANAGING DIRECTOR DIRECTOR
DIN No. 00015384 DIN No. 07095595

Place : Mumbai
Date : 19/03/2025

KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2) Share capital

Particulars	As at December 31, 2024		As at March 31, 2024	
	in Nos.	Rs. In Lakhs	in Nos.	Rs. In Lakhs
Authorised				
Equity shares of Rs. 10/ each	80,00,000	800.00	20,00,000	200.00
	80,00,000	800.00	20,00,000	200.00
Issued, Subscribed & Paid up				
Equity shares of Rs. 10/ each fully paid up	53,03,160	530.32	15,00,000	150.00
	53,03,160	530.32	15,00,000	150.00

2.1) Reconciliation of Number of Shares

Particulars	As at	As at
	December 31, 2024	March 31, 2024
	in Nos.	in Nos.
Opening Balance	15,00,000	15,00,000
Add: Right issued During the period	38,03,160	-
Less: Shares forfeited	-	-
Closing Balance	53,03,160	15,00,000

2.2) Rights, Preferences and Restrictions attached to Shares

As to Dividend

The Shares issued on Right basis shall rank Pari passu with existing equity shares of the company for the payment of dividend, if any.

As to Repayment of capital

In the event of liquidation of the Company, the holders of equity shares are entitled to receive the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.

As to Voting

The Company has only one class of shares referred to as equity shares having a face value of Rs.10. Each holder of the equity share is entitled to one vote per share.

2.3) Shares held by Holding / Ultimate Holding Company and / or their Subsidiaries / Associates

There is no Holding Company or Ultimate Holding Company of the Company. Accordingly, disclosures pertaining to shares of the Company held by held by holding company or its ultimate holding company including shares held by subsidiaries or associates of the holding company or the ultimate holding company is not applicable.

2.4) Details of Shareholders holding more than 5% Shares in the Company

Shareholders Name	As at December 31, 2024		As at March 31, 2024	
	No. of Shares	% holding	No. of Shares	% holding
Oriental Enterprises	15,97,500	30.12%	3,19,500	21.30%
Kopran Lifestyle Ltd. (Formerly known as Ridhi Sidhi Equif.Ltd.)	2,80,200	5.28%	2,80,200	18.68%
Sarvamangal Mercantile Co. Ltd.	4,20,000	7.92%	84,000	5.60%
Meenul Metallizing Pvt.Ltd.	14,38,500	27.13%	2,87,700	19.18%
Sorabh Trading Pvt. Ltd.	12,01,500	22.66%	2,40,300	16.02%

2.5) Details of shareholding of promoters

Promoter Name	As at December 31, 2024		As at March 31, 2024	
	No. of Shares	% holding	No. of Shares	% holding
Sarvamangal Mercantile Co. Ltd.	4,20,000	7.92%	84,000	5.60%
Oriental Enterprises	15,97,500	30.12%	3,19,500	21.30%
Meenul Metallizing Pvt.Ltd.	14,38,500	27.13%	2,87,700	19.18%
Suhrid Susheel Somani	6,450	0.12%	6,450	0.43%
Kopran Lifestyle Ltd. (Formerly known as Ridhi Sidhi Equif.Ltd.)	2,80,200	5.28%	2,80,200	18.68%
Bottle Closure India Pvt. Ltd.	24,000	0.45%	24,000	1.60%
Sorabh Trading Pvt. Ltd.	12,01,500	22.66%	2,40,300	16.02%
G.Claridge & Company Ltd.	60,000	1.13%	60,000	4.00%
Vandana Somani	48,150	0.91%	9,630	0.64%
Mridula Somani	48,300	0.91%	9,660	0.64%
Susheel Somani	35,100	0.66%	35,100	2.34%
Skyland Securities Pvt. Ltd.	37,200	0.70%	37,200	2.48%
Bigflex Enterprises Pvt. Ltd.	30,000	0.57%	30,000	2.00%

3) Reserves and surplus

Particulars	As at December 31, 2024	As at March 31, 2024
Surplus in Statement of Profit and Loss		
Opening Balance	5,596.87	3,768.13
Add: Profit for the period as per Statement of Profit and Loss	1,132.09	1,828.74
Less: Appropriation during the period, if any	-	-
Total	6,728.96	5,596.87



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

4) Long - term borrowings

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Secured		
From Banks - Term loan for equipment		
- Yes Bank Limited	264.05	-
- Central Bank of India	-	-
- Indusind Bank Limited	273.66	507.25
From others - Vehicle Loan	10.91	38.76
Unsecured, repayable on demand		
Loan from Directors	-	-
Total	548.62	546.01

4.1) a) Term loan for equipment from Yes Bank Limited is secured by way of hypothecation of Medical Equipments

Rate of Interest - 9.50% p.a. to 10.28% p.a.

Terms of Repayment are as under:

December 31, 2025 - Rs. 126.15 Lakhs

December 31, 2026 - Rs. 138.69 Lakhs

December 31, 2027 - Rs. 121.60 Lakhs

December 31, 2028 - Rs. 3.76 Lakhs

b) Term loan for equipment from Indusind Bank Limited is secured by way of hypothecation of Medical Equipments

Rate of Interest - 8.50% p.a. to 10.00% p.a.

Terms of Repayment are as under:

December 31, 2025 - Rs. 474.31 Lakhs

December 31, 2026 - Rs. 238.43 Lakhs

December 31, 2027 - Rs. 35.23 Lakhs

c) Vehicle Loan from MBFS India Private Limited, Bank of Maharashtra and Toyota Financial Services India Ltd. are secured by way of hypothecation of vehicle

Rate of Interest - 7.96% p.a. to 9.67% p.a.

Terms of Repayment are as under:

December 31, 2025 - Rs. 36.77 Lakhs

December 31, 2026 - Rs. 10.48 Lakhs

December 31, 2027 - Rs. 0.44 Lakhs

5) Long - term provisions

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Provision for Employee Benefits		
Gratuity	90.50	85.07
Leave encashment	53.67	51.35
Total	144.17	136.42

6) Short Term Borrowings

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Secured		
ICICI BANK CC A/c	125.57	-
Current Maturities of Long-term Borrowings (for Security, rate of interest and terms of repayment Refer Note 4.1 above)	637.23	611.08
Unsecured, repayable on demand		
Loan from Directors	-	-
Total	762.80	611.08

6.1) Cash credit facility availed from ICICI is secured by hypothecation of stock & book debts (present & future) and personal guaranteed by directors/ promoters jointly and severally.

Rate of Interest on cash credit - 9.50 % p.a.



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

7) Trade payables

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Trade Payables (including Acceptances)	-	-
(i) Total outstanding dues to micro enterprises and small enterprises (Refer Note "A" below)	1,957.57	1,625.35
(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises	-	-
Total	1,957.57	1,625.35

(A) Disclosure required under the Micro, Small and Medium Enterprises Development Act, 2006 (the Act)

Under the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED) which came into force from 2 October 2006, certain disclosures are required to be made relating to Micro and Small enterprises. There are no Micro, Small and Medium Enterprise to whom the Company owes dues which were outstanding at the balance sheet date. The above information regarding Micro, Small and Medium Enterprise has been determined to the extent such parties have been identified on the basis of the information available with the Company. This has been relied upon by the Auditors.

Particular	As at	As at
	December 31, 2024	March 31, 2024
Principal amount remaining unpaid to any supplier as at the period end.	-	-
Interest due thereon.	-	-
Amount of interest paid by the Company in terms of section 16 of the Act along with the amount of the payment made to the supplier beyond the appointed day during each accounting period.	-	-
Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the period) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006.	-	-
Amount of interest accrued and remaining unpaid at the end of the accounting period.	-	-

(B) Trade payable ageing schedule

As at December 31, 2024

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 yr.	1-2 yrs.	2-3 yrs	More than 3 yrs.	
MSME	-	-	-	-	-
Others	1,925.80	-	0.22	31.55	1,957.57
Disputed dues- MSME	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-
Unbilled dues	-	-	-	-	-
Total	1,925.80	-	0.22	31.55	1,957.57

As at March 31, 2024

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 yr.	1-2 yrs.	2-3 yrs	More than 3 yrs.	
MSME	-	-	-	-	-
Others	1,590.61	0.45	25.67	8.63	1,625.36
Disputed dues- MSME	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-
Unbilled dues	-	-	-	-	-
Total	1,590.61	0.45	25.67	8.63	1,625.36



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

8) Other current liabilities

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Interest accrued but not due on borrowings	6.92	7.11
Advance from customers	394.47	84.94
Security deposit	8.96	8.96
Payables for expenses	175.80	227.90
Employees related dues payables	65.35	106.51
Statutory liabilities	24.17	127.37
Total	675.67	562.79

9) Short - term provisions

Particulars	(Rs. In Lakhs)	
	As at	As at
	December 31, 2024	March 31, 2024
Provision for employee benefits		
Gratuity	37.92	35.65
Leave encashment	7.41	7.09
Others		
Provision for tax (Net of Advance tax and TDS)	131.86	81.95
Total	177.19	124.69



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

10 : Property, plant & equipment

Description	GROSS BLOCK					DEPRECIATION			NET BLOCK		(Rs. In Lakhs)
	As at April 01, 2024	Additions	Deletion	As at Dec 31, 2024	As at April 01, 2024	Adjustments	For the period	Deduction during the period	As at Dec 31, 2024	As at March 31, 2024	
Tangible Assets											
Diagnostic Equipments	3,796.27	452.00	-	4,248.27	930.19		232.28	-	1,162.47	2,866.08	
Computers	55.81	2.43		58.24	45.64		3.15		48.79	10.17	
Motor Car	258.30	-	19.68	238.62	103.46		19.04	16.79	105.71	154.84	
Office Equipments	29.23	1.54		30.77	22.11		1.52		23.63	7.12	
Air Conditioner	10.55	0.64		11.19	8.82		0.22		9.04	1.73	
Furniture and Fixture	12.71	-		12.71	10.38		0.18		10.56	2.33	
Total	4,162.87	456.61	19.68	4,599.80	1,120.60	-	256.39	16.79	1,360.20	3,239.59	3,042.27
Previous Year	3,412.69	778.18	28.00	4,162.87	828.80	-	294.43	2.63	1,120.60	3,042.27	2,583.88



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

11) Non current investments (Valued at Cost)

(Rs. In Lakhs)

Particulars	As at			As at	
	December 31, 2024			March 31, 2024	
	No. of Shares	Amount	Amount	No. of Shares	Amount
Long Term - Non Trade - Unquoted Equity Shares					
Parijat Shipping & Finale Ltd. of Rs.10/-each fully paid up	35,14,080		282.91	8,78,520	19.35
Long Term - Non Trade - Quoted Equity Shares					
Sarvamangal Mercantile Co Ltd. of Rs.10/-each fully paid up				18,000	
Less : Provision in diminution in value of Investment			-		
Total			282.91		19.35

Aggregate amount of Quoted Investments	-	0.90
Aggregate Market Value of Quoted Investments	-	9.00
Aggregate amount of Unquoted Investments	282.91	19.35
Aggregate Provision for Diminution in value of Investments	-	0.90

12) Deferred tax assets / (liabilities) (net)

(Rs. In Lakhs)

Particulars	As at	As at
	December 31, 2024	March 31, 2024
Deferred Tax Liabilities		
Depreciation on Property, plant and equipment	(154.55)	(140.59)
Deferred Tax Assets		
Post Employment Benefits and Provision for Diminution in value of Investments	47.69	45.32
Others	-	-
Deferred tax assets / (liabilities) (net)	(106.86)	(95.28)

13) Other Non-current assets

(Rs. In Lakhs)

Particulars	As at	As at
	December 31, 2024	March 31, 2024
Unsecured, considered good		
Security deposit	3.97	3.97
Other assets	-	0.44
Total	3.97	4.41

14) Inventories

(Rs. In Lakhs)

Particulars	As at	As at
	December 31, 2024	March 31, 2024
(Valued at lower of cost and net realisable value)		
Stock-in-trade		
Reagent	796.65	195.00
Medical Equipments	439.31	328.48
Spares	239.44	174.24
Total	1,475.40	697.72



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

15) Trade receivables

Particulars	(Rs. in Lakhs)	
	As at December 31, 2024	As at March 31, 2024
(Unsecured, Considered Good)	2,202.37	3,319.47
Total	2,202.37	3,319.47

Trade receivables ageing schedule
As at Dec 31, 2024

Particular	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 yrs.	2-3 yrs	More than 3 yrs.	
Undisputed - Considered Good	1,663.99	198.28	234.64	105.46	-	2,202.37
Undisputed - Considered Doubtful	-	-	-	-	-	-
Disputed - Considered Good	-	-	-	-	-	-
Disputed - Considered Doubtful	-	-	-	-	-	-
Total	1,663.99	198.28	234.64	105.46	-	2,202.37

As at March 31, 2024

Particular	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 yrs.	2-3 yrs	More than 3 yrs.	
Undisputed - Considered Good	2,950.34	227.00	91.73	25.21	25.19	3,319.47
Undisputed - Considered Doubtful	-	-	-	-	-	-
Disputed - Considered Good	-	-	-	-	-	-
Disputed - Considered Doubtful	-	-	-	-	-	-
Total	2,950.34	227.00	91.73	25.21	25.19	3,319.47



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

16) Cash and bank balances

Particulars	(Rs. In Lakhs)	
	As at December 31, 2024	As at March 31, 2024
Cash & Cash Equivalents		
Cash on Hand	4.25	5.04
HDFC LIQUID FUND POST IPO COLLN A/C	2,619.00	500.00
Balances with Banks		
in Current Accounts	468.92	325.91
Fixed Deposits with Banks (Maturity of less than 3 months)		
Other Bank Balances		
Fixed deposits with Banks (Maturity of more than 3 months & less than 12 months)		169.55
Fixed deposits with Banks (Maturity of more than 12 months)	175.56	533.01
Fixed deposits with Banks, marked as a margin money against the guarantees and letter of credit	500.00	212.00
Total	3,767.73	1,745.52

17) Short-term loans and advances

Particulars	(Rs. In Lakhs)	
	As at December 31, 2024	As at March 31, 2024
Deposits	259.89	240.21
Other loans & advances	141.93	133.77
Total	401.82	373.98

18) Other current assets

Particulars	(Rs. In Lakhs)	
	As at December 31, 2024	As at March 31, 2024
Interest accrued but not due	38.76	112.46
Income Accrued But Not Due	-	
Prepaid expenses	47.46	38.38
Advances to creditors	74.02	4.54
Balance with Government Authorities	94.04	83.18
Advances recoverable in cash or kind	4.09	7.23
Total	258.37	245.78



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

19) Revenue from operations

Particulars	(Rs. In Lakhs)	
	Period Ended December 31, 2024	Year Ended March 31, 2024
Sales of product	6,758.16	10,149.60
Other operating income		
Service Charges (TDS Rs. 8,06,212.95, P.Y. Rs.7,81,559.96)	66.60	90.87
Commission	-	-
Total	6,824.76	10,240.46

20) Other Income

Particulars	(Rs. In Lakhs)	
	Period Ended December 31, 2024	Year Ended March 31, 2024
Interest (TDS Rs.4,41,196/-, P.Y.Rs.2,52,777/-)	23.24	89.72
Unrelaised Income	119.00	
Insurance claim recd	2.84	-
Profit & Loss on Sale of Investment	8.55	-
Net gain on foreign currency transaction and translation	6.19	15.22
Sundry balances w/back	-	-
Profit on Sale of Fixed Assets	0.11	-
Bad debts recovered	-	-
Provision in Diminution on Value of Investment	0.90	-
Total	160.83	104.94

21) Purchase of stock-in-trade

Particulars	(Rs. In Lakhs)	
	Period Ended December 31, 2024	Year Ended March 31, 2024
Reagents, spares and consumables & Medical Equipments	3,148.65	3,576.07
	702.95	992.27
Total	3,851.60	4,568.34

22) Changes in Inventory of Stock-in-Trade

Particulars	(Rs. In Lakhs)	
	Period Ended December 31, 2024	Year Ended March 31, 2024
Opening Stock	697.72	920.69
Less : Closing Stock	1,475.40	697.72
Total	(777.68)	222.97

23) Employee benefit expense

Particulars	(Rs. In Lakhs)	
	Period Ended December 31, 2024	Year Ended March 31, 2024
Salaries, wages and bonus	695.85	1,073.02
Contribution to provident and other Fund	34.02	40.39
Staff welfare expense	21.23	39.73
Total	751.10	1,153.14



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

24) Finance cost

Particulars	(Rs. In Lakhs)	
	Period Ended	Year Ended
	December 31, 2024	March 31, 2024
Interest expense	92.86	121.15
Loan processing charges	1.89	3.91
Bank charges	23.81	24.12
Total	118.56	149.18

25) Other Expenses

Particulars	(Rs. In Lakhs)	
	Period Ended	Year Ended
	December 31, 2024	March 31, 2024
Rent, Rates & Taxes	140.69	41.68
Payment to Auditors		
Auditor's Remuneration (Refer Note 'A' below)	3.30	2.30
Advertisement	0.90	0.71
CSR Expenses	68.08	22.00
General & Labour Charges	10.99	14.93
Repairs & Maintenance	43.62	94.05
Electricity Charges	6.60	7.30
Conference and Training Expenses	31.00	45.79
Commission on Sales	206.18	400.16
Sales Promotion Expenses	32.02	50.19
Packing, Freight and Forwarding	197.82	140.87
Printing and Stationery	3.37	7.95
Postage, Telegram and Telephone	6.70	8.88
Travelling and Conveyance	322.29	381.34
Legal and Professional Fees	136.05	157.15
Installation Charges	43.15	40.83
Bad debts	-	3.32
GST Dues	2.36	1.72
License Fees	3.73	11.49
Net loss on foreign currency transaction and translation	-	-
Sundry Balance W/off	-	-
Loss on Sale of Fixed Assets	-	0.37
Miscellaneous Expenses	14.67	37.02
Total	1,273.52	1,470.05
(A) Auditor's Remuneration		
For statutory audit	2.50	1.50
For Tax audit	0.80	0.80
Total	3.30	2.30

26) Earnings per Equity Share

Particulars	Period Ended	Year Ended
	December 31, 2024	March 31, 2024
Number of Equity Shares	53,03,160	15,00,000
Weighted average number of Equity Shares	26,62,914	15,00,000
Face Value per share (Rs.)	10	10
Profit after tax available to Equity Shareholders (Rs.)	1,132.09	1,828.73
Basic and Diluted Earning Per Share (Rs.)	42.51	121.92



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. CORPORATE INFORMATION

Kopran Laboratories Limited ('the Company') is a public limited company domiciled and incorporated in India having its registered office at Parijat House, 1076, DR. E. Moses Road, Worli, Mumbai - 400 018, India. The company is carrying on the business of trading of medical equipment, reagents and consumables, provides laboratory automation solutions and delivers projects in hospital infrastructure.

The financial statements for the period April 01, 2024 to December 31, 2024, have been reviewed by audit committee and approved & authorized for issue by the Board of Directors of the Company in their meeting held on March 19, 2025.

2. SIGNIFICANT ACCOUNTING POLICIES

2.1. Basis of Preparation of Financial Statements

These financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on the accrual basis, Pursuant to Section 133 of the Companies Act, 2013 ('the Act') read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied.

The presentation is based on the Schedule III of the Companies Act, 2013. All assets and liabilities are classified into current and non-current generally based on the criteria of realization / settlement within nine months period from the balance sheet date.

2.2 Use of Estimates

The preparation of the financial statements in conformity with GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent assets and liabilities as at the date of the financial statements and reported amounts of income and expenses during the period. Examples of such estimates include provisions for doubtful debts, future obligations under employee retirement benefit plans, income taxes, post-sales customer support and the useful lives of Property, Plant and Equipment and intangible assets. The difference between the actual result and estimate are recognised in the period in which results are known or materialised.



2.3. Revenue Recognition

- i. Sale comprises of sale of goods net of trade discounts. It is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured and is recognized on accrual basis.
- ii. Service charges and Commission income is recognized as and when accrued in terms of the agreement with the customer over the period of the contract.
- iii. Interest income is recognized on time proportion basis taking into account the amount invested and the rate of interest.

2.4. Property, Plant and Equipment and Depreciation

- i. All Property, Plant and Equipment are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.
- ii. Effective 1st April 2014, the Company depreciates its Property, Plant and Equipment over the useful life as per Schedule II of The Companies Act, 2013 except in case of Building Improvements which are depreciated over the estimated useful life of 10 years.
- iii. Depreciation on Property, Plant and Equipment added/disposed off during the period is provided for on pro-rata basis with reference to date of installation /put to use/ date of sale.
- iv. Intangible assets are recognized only if it is probable that the future economic benefits that are attributable to the asset-will flow to the enterprise and the cost of the asset can be measured reliably. The intangible assets are recorded at cost and are carried at cost less accumulated amortization.
- v. Capital Work in Progress is stated at cost, comprising of direct Cost, attributable borrowing cost and related incidental expenditure. All expenses incurred for acquiring, erecting and commissioning of fixed assets and incidental expenditure incurred during construction of the projects are shown under Capital Work in Progress. The advances given for acquiring fixed assets are shown under Capital Work in Progress.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.5. Investments

- i. Investments are classified into Current Investment and Non-Current Investments.
- ii. Non-Current Investments are carried at cost. Provision for diminution is made only if, in the opinion of the management, such a decline is other than temporary.
- iii. Quoted Investments are valued at cost or market value whichever is lower. Unquoted investments are stated at cost. The decline in the value of the unquoted investments, other than temporary, is provided for. Cost is inclusive of brokerage, fees and duties but excludes Securities Transaction Tax, if any.

2.6. Inventories

Inventories are valued at cost or net realisable value whichever is lower. Cost of inventories comprises all costs of purchase and other costs incurred in bringing the inventories to their present location and condition.

2.7. Impairment of Assets

The Property, Plant and Equipment are reviewed for impairment at each balance sheet date. In case of any such indication, the recoverable amount of these assets is determined and if such recoverable amount of the asset or cash generating unit to which the assets belongs is less than its carrying amount, the impairment loss is recognised by writing down such assets to their recoverable amount. An impairment loss is reversed if there is change in the recoverable amount and such loss either no longer exists or has decreased.

2.8. Foreign Currency Transactions

- i. Foreign currency transactions are recorded at the exchange rate prevailing on the date of transaction. Exchange difference arising on settlement/conversion is adjusted to Statement of Profit & Loss.
- ii. Monetary assets and liabilities denominated in foreign currencies as at the Balance Sheet date are translated at the closing exchange rates on that date; the resultant exchange differences are recognized in the Statement of Profit and Loss.



2.9. Employee Benefits

1. Short Term Employee Benefits

All employee benefits payable wholly within nine months of rendering the service are classified as short-term employee benefits. Undiscounted value of benefits such as salaries and bonus are recognized in the period in which the employee renders the related service

2. Defined contribution plans

All employees of the Company are entitled to receive benefits under the Provident Fund, which is a defined contribution plan. Both the employees and the employer make monthly contributions to the plan at a predetermined rate (presently 12%) of the employees' basic salary. These contributions are made to the fund administered and managed by the Government of India.

The Company's contributions to Provident Fund and employees' state insurance schemes are expensed. The Company has no further obligations under these plans beyond its monthly contributions.

3. Defined benefit plans

i. Gratuity

Liability in respect of gratuity is determined using the projected unit credit method with actuarial valuations as on the balance sheet date and gains/losses are recognized immediately in the Statement of Profit & Loss.

ii. Leave Encashment

Liability in respect of leave encashment is determined using the projected unit credit method with actuarial valuations as on the balance sheet date and gains/losses are recognized immediately in the Statement of Profit & Loss.



2.10. Borrowing Cost

Borrowing costs that are directly attributable to the acquisition, construction or production of qualifying assets till the time they are ready for intended use are capitalized as part of cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. Other borrowing costs are recognized as an expense in the period in which they are incurred.

2.11. Earnings per Share

In accordance with the Accounting Standard (AS) – 20 “Earnings Per Share” issued by the Institute of Chartered Accountants of India, basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all potential dilutive equity shares, except where result would be anti-dilutive.

2.12. Income Tax

Provision for current tax is made on the basis of estimated taxable income for the current accounting period in accordance with the Income Tax Act, 1961. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences, subject to the consideration of prudence. Deferred tax assets and liabilities are measured using the tax rates enacted or substantively enacted by the balance sheet date. The carrying amount of deferred tax asset / liability is reviewed at each balance sheet date.

2.13. Prior Period Items

Prior period expenses/income is accounted under the respective heads. Material items, if any, are disclosed separately by way of a note.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.14. Provisions & Contingent Liabilities

The Company creates a provision when there is a present obligation as a result of an obligating event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

2.15. Other Accounting Policies

These are consistent with the generally accepted accounting practices.

27. Contingent Liabilities not provided for:

Particulars	For the period ended December 31, 2024 (Rs. in lakhs)	For the year ended March 31, 2024 (Rs. in lakhs)
Bank Guarantees	692.37	759.62

28. Accounting Ratios with calculations:

Particulars	Formula	Apr-24 to Dec-24	2023-24	% Change during the period	Reason for Change
1. Current Ratio	Current Assets /Current Liabilities	2.26	2.18	3.41%	-
2. Debt-Equity Ratio	Total Debt /Shareholders Equity	0.18	0.20	-10.06%	-
3. Debt Service Coverage Ratio	Earnings available for Debt Service /Debt Service	1.95	3.73	-47.57%	-
4. Return on Equity	Net Profit after tax /Average Shareholder's Equity	0.17	0.38	-54.65%	-
5. Inventory Turnover Ratio	Cost of Goods Sold /Average Inventory	2.83	5.92	-52.22%	-
6. Trade Receivables Turnover Ratio	Net Credit Sales /Average Accounts Receivable	2.47	3.96	-37.60%	-



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

7. Trade Payables Turnover Ratio	Net Credit Purchases / Average Trade Payables	2.15	3.42	-37.16%	-
8. Net Capital Turnover Ratio	Net Sales / Working Capital	1.71	2.96	-48.95%	-
9. Net Profit Ratio	Net Profit/Net Sales	0.16	0.18	-8.55%	-
10. Return on Capital Employed	EBIT/Capital Employed	0.19	0.38	-50.01%	-
11. Return on Investment	Income generated from investments / Average Investments	0.11	0.02	431.98%	Not applicable in FY 21-22

29. During the period the company have imported good worth the following on CIF value:

Particulars	For the period ended	For the year ended
	December 31, 2024	March 31, 2024
	(Rs. in lakhs)	(Rs. in lakhs)
Reagent	903.99	456.12
Medical equipment	254.31	415.41
Spares and consumables	108.54	301.09
Total	1,266.82	1,172.62

30. In the opinion of the Board, all current assets, loans & advances and other receivables are approximately of the value stated, if realised in the ordinary course of business.

31. Disclosure of related parties/related party transactions pursuant to Accounting Standard (AS) 18 "Related Party Disclosures"

a) List of related parties

Sr. No.	Nature of Relationship	Name of Related Parties
I	Key Management Personnel	Mr. Varun Somani
		Mr. Adarsh Somani
II	Relative of Key Management Personnel (KMP)	Mr. Surendra Somani
		Mrs. Namrata Somani
		Mrs. Nupur Somani
		Mrs. Vandana Somani
		Mrs. Mridula Somani
III	Enterprise having Significant Influence	Sarvamangal Mercantile Co Ltd
IV	Enterprise over which either KMP or their relative have Significant Influence	Kopran Limited
		Oricon Enterprises Limited



b) Transactions with Related Parties

Sr. No.	Name of Related party	Transaction during the period	December 31, 2024 (Rs. in Lakhs)	March 31, 2024 (Rs. in Lakhs)
1	Mr. Varun Somani	Salary & Perks	98.56	112.40
		Commission	NIL	90.00
		Loan Taken	NIL	NIL
		Loan Repaid	NIL	124.00
2	Mr. Adarsh Somani	Loan Taken	NIL	NIL
		Loan Repaid	NIL	14.50
3	Mrs. Namrata Somani	Loan Taken	NIL	NIL
		Loan Repaid	NIL	181.50
4	Kopran Limited	Exp. Charges Paid	NIL	NIL

Outstanding Balances

Sr. No.	Name of Related party	Outstanding Balances	December 31, 2024 (Rs. in Lakhs)	March 31, 2024 (Rs. in Lakhs)
1	Mr. Varun Somani	Loan Outstanding	NIL	NIL
2	Mr. Adarsh Somani	Loan Outstanding	NIL	NIL
3	Mrs. Namrata Somani	Loan Outstanding	NIL	NIL
4	Oricon Enterprises Ltd.	Payable	3.59	3.59

32. Disclosures pursuant to Accounting Standard (AS) 17 "Segment Reporting

The company operates in a single business segment viz. business of trading of medical equipment and chemical knowns as 'reagents' products and accordingly there is no reportable business or geographical segments as prescribed Under Accounting Standard 17 "Segment Reporting".

33. Expenditure incurred in foreign currency

Particulars	For the period ended December 31, 2024 (Rs. in lakhs)	For the year ended March 31, 2024 (Rs. in lakhs)
Travelling and Conveyance	85.05	65.85
Conference and training expenses	NIL	NIL



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS****34. Corporate Social Responsibility**

As per section 135 of the Companies Act, 2013, amount required to be spent by the Company during the period ended December 31, 2024 and March 31, 2024 is Rs. 30.85 lakhs and Rs. 17.94 lakhs, respectively, computed at 2% of its average net profit for the immediately preceding three financial years, on Corporate Social Responsibility (CSR). The Company incurred an amount of Rs. 68.08 lakhs and Rs. 22.00 lakhs during the period ended December 31, 2024 and March 31, 2024, respectively, towards CSR expenditure for purposes other than construction / acquisition of any asset.

Particulars	For the period ended December 31, 2024 (Rs.in lakhs)	For the year ended March 31, 2024 (Rs. in lakhs)
i) Amount required to be spent by the Company during the period	30.85	17.94
ii) Amount of expenditure incurred	68.08	22.00
iii) Shortfall at the end of the period	NIL	NIL
iv) Total of Previous years Shortfall	NIL	NIL
v) Reason for Shortfall	NIL	NIL
vi) Nature of CSR Activities	Education to underprivileged Children and healthcare for poor people	Education to underprivileged Children, also provided food, shelter and healthcare to children
vii) Details of related party transactions e.g. Contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant Accounting Standard	NIL	NIL
viii) Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the period should be shown	NIL	NIL

35. Details of Loans given, covered u/s 186 (4) of the Companies Act, 2013

Particulars	For the period ended December 31, 2024 (Rs. in lakhs)	For the year ended March 31, 2024 (Rs. in lakhs)
Loans and advances in the nature of loans		
Pankaj Trading Corporation		
Loans given during the period	NIL	NIL



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Balance as at the period end	NIL	NIL
Maximum amount outstanding at any time during the period	NIL	100.00
Purpose: To be used for principal business activity of the borrower		

36. Other Disclosures

- i. There were no litigations and proceedings pending as at December 31, 2024.
- ii. The Company did not have any outstanding long - term contracts including derivative contracts as at December 31, 2024.
- iii. There is no amount required to be transferred to the Investor Education and Protection Fund by the Company.

37. Additional Regulatory Information

- i. There are no immovable properties held in the name of the Company.
- ii. As the Company have not revalued its Property, Plant and Equipment, accordingly compliance with Rule 2 of Companies (Registered Valuers and Valuation) Rules, 2017 does not arise.
- iii. The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties, as defined under the Companies Act, 2013, either severally or jointly with any other person that repayable on demand or without specifying any term or period of repayment.
- iv. The Company does not have any intangible assets under development.
- v. The Company does not have any Benami Property under the Benami Transactions (Prohibition) Act, 1988.
- vi. The Company has availed borrowings from banks or financial institutions on the basis of security of stock and book debts. The Company has filed quarterly returns or statement Company with banks or financial institution and there are no material discrepancies observed between the quarterly returns or statement filed and the books of account.
- vii. The Company has not been declared as wilful defaulter by any bank or financial institutions or government or government authority.
- viii. The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

- ix. The Company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the current period.
- x. The Company does not have any identified transaction with struck off company during the current period.
- xi. The Company has not traded or invested in Crypto currency or Virtual Currency during the current period.
- xii. The Company has not advanced or loaned or invested funds to any other person(s) or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- xiii. The Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- xiv. The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the period in the tax assessments under the Income-tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income-tax Act, 1961
- xv. The Company does not have any subsidiary as at the balance sheet date, accordingly compliance with section 2(89) of the Companies Act read with Companies (Restriction on number of layers) Rules, 2017 does not arise.
38. Previous year's figures are regrouped and rearranged wherever considered necessary to correspond with the current period's classification / disclosure.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

As per our report of even date

For KHANDELWAL JAIN & CO

Chartered Accountants

Firm Registration No. - 105049W

Bhupendra Karkhanis

Bhupendra Karkhanis
PARTNER

Membership No. 108336



For and on behalf of Board of Directors

Varun Somani

VARUN SOMANI
MANAGING DIRECTOR

DIN No. 00015384

Namrata Somani

NAMRATA SOMANI
DIRECTOR

DIN No. 07095595

Place: Mumbai

Date : 19/03/2025